Anti-Inflammatory Drugs Market to Reach US$198.92 Billion by 2031, Growing at 8.7% CAGR by 2031 | North America Holds Significant Market Share | DataM Intelligence

Leander, Texas and Tokyo, Japan - Dec 03, 2025
According to DataM Intelligence, the global anti-inflammatory drugs market reached US$102.72 billion in 2023 and is expected to reach US$198.92 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031. This robust growth is propelled by the rising global burden of chronic inflammatory diseases, increasing geriatric population, growing adoption of biologic therapies, advancements in targeted drug delivery, and rising awareness and diagnosis of autoimmune and inflammatory conditions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/anti-inflammatory-drugs-market?jd

Report Details:
• No. of Pages: 180
• Forecast Period: 2024-2031
• Market Size (2023): $102.72 Billion
• Market Size (2031): $198.92 Billion
• Compound Annual Growth Rate: 8.7%
• Regions Covered: Global

Global Recent Developments:
✅ November 2025: Johnson & Johnson received FDA approval for a novel, oral JAK-1 selective inhibitor with a superior cardiovascular safety profile, positioned to capture significant share in the Arthritis segment and challenge the safety concerns of earlier JAK inhibitors.
✅ November 2025: Gilead Sciences acquired a biotech company specializing in gut-restricted, Oral therapies for Inflammatory Bowel Disease (IBD), aiming to develop safer systemic exposure profiles compared to current immunosuppressants.
✅ October 2025: Novartis announced positive Phase 3 results for its IL-17A/F nanobody (given via Inhalation) for severe Asthma, demonstrating superiority over standard biologics and representing a major innovation in Route of Administration for pulmonary inflammation.
✅ October 2025: Pfizer and BioNTech presented preclinical data on an mRNA-based therapy designed to locally express an anti-inflammatory cytokine in arthritic joints, potentially creating a new class within Drug Class beyond traditional small molecules and biologics.
✅ September 2025: The first biosimilar for AbbVie's Humira (adalimumab) launched in the US at an 85% discount, triggering a massive shift in the Anti-Inflammatory Biologics market and dramatically increasing patient access for Inflammatory Bowel Disease (IBD) and arthritis.

Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market

Competitive Landscape
The market is highly competitive, split between large pharmaceutical companies dominating biologic innovation and generic manufacturers supplying traditional therapies.

1. AbbVie Inc. maintained leadership, particularly in immunology with Humira and newer agents like Skyrizi and Rinvoq, though facing intense biosimilar competition.
2. Johnson & Johnson held a strong position across multiple Applications (Arthritis, IBD, Psoriasis) with blockbusters like Stelara and Tremfya, and a robust pipeline.
3. Pfizer Inc. remained a key player with its Xeljanz franchise (despite safety label updates) and a strong portfolio of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Celebrex.
4. Novartis AG led in innovative delivery and new mechanisms, particularly in dermatology and respiratory inflammation with Cosentyx and emerging inhaled biologics.
5. Amgen and Bristol Myers Squibb held significant shares with Enbrel and Orencia, respectively, while navigating the biosimilar and novel therapy landscape.

Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/anti-inflammatory-drugs-market?jd

Segmentation Analysis
By Drug Class
• Anti-Inflammatory Biologics (e.g., TNF inhibitors, IL inhibitors, JAK inhibitors) is the largest and fastest-growing segment, driving overall market growth due to their high efficacy in treating severe autoimmune diseases. However, the segment is undergoing a major transformation with the entry of biosimilars, increasing access and competition.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs) represent a large, mature volume segment for mild-to-moderate pain and inflammation, available widely through Retail Pharmacies.

By Application
• Arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis) is the dominant Application segment, accounting for the largest revenue share due to high prevalence and the widespread use of high-cost biologics and targeted synthetics.
• Inflammatory Bowel Disease (IBD) and Asthma are other major, high-growth segments fueled by biologic adoption.
By Route of Administration
• Injection remains the primary route for biologics, but innovation is strong in Oral formulations (e.g., JAK inhibitors, gut-restricted therapies) and localized delivery (Topical, Inhalation) to improve safety profiles.

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?jd

Regional Analysis:
North America is expected to hold a significant position in the anti-inflammatory drugs market share, driven by high healthcare expenditure, favorable reimbursement for expensive biologic therapies, a high prevalence of autoimmune diseases, early adoption of novel treatments, and strong presence of leading pharmaceutical companies.

Asia Pacific is growing at the fastest pace in the anti-inflammatory drugs market, fueled by its massive population base, rising prevalence of lifestyle and age-related inflammatory diseases, improving healthcare infrastructure and diagnosis rates, increasing health insurance penetration, and growing market entry of both innovative drugs and biosimilars at more accessible price points.

Market Trends & Drivers
The market is evolving from broad immunosuppression to targeted, pathway-specific therapies with improved safety. Key trends include the rapid expansion of biosimilars reducing costs and increasing biologic access, the development of oral and targeted-delivery options to replace injections, increased focus on precision medicine to match patients with the most effective biologic based on biomarkers, and rising R&D in novel mechanisms beyond cytokine blockade (e.g., cellular therapies, gene therapies). The aging global population, growing disease burden, and therapeutic innovation are the core market drivers.

Related Reports:
1. Autoimmune Diagnostics Market - https://www.datamintelligence.com/research-report/autoimmune-diagnostics-market?jd
2. Biosimilars Market - https://www.datamintelligence.com/research-report/biosimilars-market?jd
3. Pain Management Drugs Market - https://www.datamintelligence.com/research-report/pain-management-drugs-market?jd

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.